Bharat Biotech & Partners develop an indegenous rotavirus vaccine
The two candidate vaccines represent the products of two independent research teams from RVDP who have worked in parallel for more than a decade under the auspices of the Indo-US Vaccine Action Program (VAP) and have combined their efforts through the RVDP. The phase-I clinical trial in India has been carried out by Society for Applied Studies, New Delhi. The RVDP receives financial support primarily from the Gates Foundation, through the Program for Appropriate Technology in Health (PATH), Seattle, with additional support from the Indo-US VAP, the Department of Biotechnology, and Govt. of India.
Following the encouraging results of this phase I trial using pilot lots of the candidate rotavirus vaccines manufactured at the National Institutes of Health, USA, the RVDP is planning clinical trials with cGMP vaccine lots produced by Bharat Biotech, using the same strains, 116E and I321. Bharat Biotech International Limited Hyderabad is a leading manufacturer of vaccines and biotherapeutics in India. Bharat Biotech has successfully developed the 116E and I321 human rotavirus strains as vaccine candidates. The 116E and I321 vaccine candidates have undergone extensive characterization and quality control testing at Bharat Biotech and at external agencies with the global standards. These trials are planned to begin in Q2 of 2006.
Most read news
Organizations
Other news from the department science
Get the life science industry in your inbox
From now on, don't miss a thing: Our newsletter for biotechnology, pharma and life sciences brings you up to date every Tuesday and Thursday. The latest industry news, product highlights and innovations - compact and easy to understand in your inbox. Researched by us so you don't have to.